Trial Outcomes & Findings for A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer (NCT NCT00615420)
NCT ID: NCT00615420
Last Updated: 2019-06-05
Results Overview
Worst Radiation Therapy Oncology Group (RTOG) score greater than or equal to Grade 3 mucositis The scale ranges from Grade 0 (No mucositis) to Grade 4 (Necrosis or deep ulceration ± bleeding) where Grade 0 is the best outcome and Grade 4 is the worst outcome.
COMPLETED
PHASE3
106 participants
Over 7 weeks of expected duration of mucositis
2019-06-05
Participant Flow
Participant milestones
| Measure |
Honey
Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed
manuka honey: Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
|
Placebo
Sugar-free placebo gel 5ml 4 times a day, swished and held in mouth for 30 secs then swallowed
placebo gel: Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
|
|---|---|---|
|
Overall Study
STARTED
|
54
|
52
|
|
Overall Study
COMPLETED
|
23
|
25
|
|
Overall Study
NOT COMPLETED
|
31
|
27
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Not all patients have baseline information available
Baseline characteristics by cohort
| Measure |
Honey
n=54 Participants
Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed
manuka honey: Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
|
Placebo
n=52 Participants
Sugar-free placebo gel 5ml 4 times a day, swished and held in mouth for 30 secs then swallowed
placebo gel: Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
|
Total
n=106 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
56.8 years
n=52 Participants • Not all patients have baseline information available
|
59.5 years
n=48 Participants • Not all patients have baseline information available
|
58.1 years
n=100 Participants • Not all patients have baseline information available
|
|
Sex: Female, Male
Female
|
10 Participants
n=54 Participants • Not all patients have baseline information available
|
8 Participants
n=50 Participants • Not all patients have baseline information available
|
18 Participants
n=104 Participants • Not all patients have baseline information available
|
|
Sex: Female, Male
Male
|
44 Participants
n=54 Participants • Not all patients have baseline information available
|
42 Participants
n=50 Participants • Not all patients have baseline information available
|
86 Participants
n=104 Participants • Not all patients have baseline information available
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
|
Weight
|
85.6 kg
STANDARD_DEVIATION 19.3 • n=52 Participants • Not all patients have baseline information available
|
79.6 kg
STANDARD_DEVIATION 15.2 • n=50 Participants • Not all patients have baseline information available
|
82.7 kg
STANDARD_DEVIATION 17.6 • n=102 Participants • Not all patients have baseline information available
|
|
Diabetic
|
3 Participants
n=54 Participants
|
10 Participants
n=52 Participants
|
13 Participants
n=106 Participants
|
|
Smoker
|
9 Participants
n=54 Participants
|
7 Participants
n=52 Participants
|
16 Participants
n=106 Participants
|
|
ECOG > 0
|
8 Participants
n=54 Participants
|
13 Participants
n=52 Participants
|
21 Participants
n=106 Participants
|
|
Chemotherapy
|
31 Participants
n=54 Participants
|
35 Participants
n=52 Participants
|
66 Participants
n=106 Participants
|
|
Radiation Therapy => 7,000 Gy
|
36 Participants
n=54 Participants
|
30 Participants
n=52 Participants
|
66 Participants
n=106 Participants
|
PRIMARY outcome
Timeframe: Over 7 weeks of expected duration of mucositisPopulation: Patients who had at least one mucositis assessment were included in this analysis
Worst Radiation Therapy Oncology Group (RTOG) score greater than or equal to Grade 3 mucositis The scale ranges from Grade 0 (No mucositis) to Grade 4 (Necrosis or deep ulceration ± bleeding) where Grade 0 is the best outcome and Grade 4 is the worst outcome.
Outcome measures
| Measure |
Honey
n=40 Participants
Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed
manuka honey: Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
|
Placebo
n=41 Participants
Sugar-free placebo gel 5ml 4 times a day, swished and held in mouth for 30 secs then swallowed
placebo gel: Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
|
|---|---|---|
|
Severity of Mucositis According to the Radiation Therapy Oncology Group (RTOG) for Patients Who Had at Least One Mucositis Assessment
|
14 Participants
|
18 Participants
|
PRIMARY outcome
Timeframe: Over 7 weeks of expected duration of mucositisPopulation: Patients who had a minimum of 2 mucositis assessments were included in this analysis
Worst Radiation Therapy Oncology Group (RTOG) score greater than or equal to Grade 3 mucositis The scale ranges from Grade 0 (No mucositis) to Grade 4 (Necrosis or deep ulceration ± bleeding) where Grade 0 is the best outcome and Grade 4 is the worst outcome.
Outcome measures
| Measure |
Honey
n=31 Participants
Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed
manuka honey: Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
|
Placebo
n=33 Participants
Sugar-free placebo gel 5ml 4 times a day, swished and held in mouth for 30 secs then swallowed
placebo gel: Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
|
|---|---|---|
|
Severity of Mucositis According to the Radiation Therapy Oncology Group (RTOG) for Patients Who Had a Minimum of 2 Mucositis Assessments
|
11 Participants
|
16 Participants
|
Adverse Events
Honey
Placebo
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Honey
n=54 participants at risk
Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed
manuka honey: Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
|
Placebo
n=52 participants at risk
Sugar-free placebo gel 5ml 4 times a day, swished and held in mouth for 30 secs then swallowed
placebo gel: Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
|
|---|---|---|
|
Gastrointestinal disorders
Nausea
|
14.8%
8/54
|
9.6%
5/52
|
|
Product Issues
Bad Taste
|
0.00%
0/54
|
1.9%
1/52
|
|
Product Issues
Burning Sensation in Mouth
|
3.7%
2/54
|
0.00%
0/52
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place